Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.37EUR
18.69 MEUR
47.82 MEUR
40.11 M
About CLINUVEL PHARMACEUTICALS LIMITED
Sector
CEO
Philippe Jacques Wolgen
Headquarters
Melbourne
Website
Founded
1999
ISIN
AU000000CUV3
FIGI
BBG000C0XL84
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of UR9 is 9.38 EUR — it has increased by 0.91% in the past 24 hours. Watch CLINUVEL PHARMACEUTICALS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CLINUVEL PHARMACEUTICALS LTD stocks are traded under the ticker UR9.
UR9 stock has risen by 2.12% compared to the previous week, the month change is a 0.59% rise, over the last year CLINUVEL PHARMACEUTICALS LTD has showed a 15.39% decrease.
We've gathered analysts' opinions on CLINUVEL PHARMACEUTICALS LTD future price: according to them, UR9 price has a max estimate of 13.83 EUR and a min estimate of 13.83 EUR. Watch UR9 chart and read a more detailed CLINUVEL PHARMACEUTICALS LTD stock forecast: see what analysts think of CLINUVEL PHARMACEUTICALS LTD and suggest that you do with its stocks.
UR9 stock is 1.98% volatile and has beta coefficient of −0.12. Track CLINUVEL PHARMACEUTICALS LTD stock price on the chart and check out the list of the most volatile stocks — is CLINUVEL PHARMACEUTICALS LTD there?
Today CLINUVEL PHARMACEUTICALS LTD has the market capitalization of 479.46 M, it has decreased by 0.65% over the last week.
Yes, you can track CLINUVEL PHARMACEUTICALS LTD financials in yearly and quarterly reports right on TradingView.
CLINUVEL PHARMACEUTICALS LTD is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
UR9 earnings for the last half-year are 0.13 EUR per share, whereas the estimation was 0.16 EUR, resulting in a −17.65% surprise. The estimated earnings for the next half-year are 0.31 EUR per share. See more details about CLINUVEL PHARMACEUTICALS LTD earnings.
CLINUVEL PHARMACEUTICALS LTD revenue for the last half-year amounts to 19.90 M EUR, despite the estimated figure of 21.46 M EUR. In the next half-year revenue is expected to reach 33.39 M EUR.
UR9 net income for the last half-year is 6.75 M EUR, while the previous report showed 11.73 M EUR of net income which accounts for −42.51% change. Track more CLINUVEL PHARMACEUTICALS LTD financial stats to get the full picture.
Yes, UR9 dividends are paid annually. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (TTM)% is 0.32%. Tracking CLINUVEL PHARMACEUTICALS LTD dividends might help you take more informed decisions.
CLINUVEL PHARMACEUTICALS LTD dividend yield was 0.28% in 2023, and payout ratio reached 8.07%. The year before the numbers were 0.27% and 9.47% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLINUVEL PHARMACEUTICALS LTD EBITDA is 24.83 M EUR, and current EBITDA margin is 53.24%. See more stats in CLINUVEL PHARMACEUTICALS LTD financial statements.
Like other stocks, UR9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLINUVEL PHARMACEUTICALS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLINUVEL PHARMACEUTICALS LTD technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLINUVEL PHARMACEUTICALS LTD stock shows the sell signal. See more of CLINUVEL PHARMACEUTICALS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.